GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Poolbeg Pharma PLC (OTCPK:POLBF) » Definitions » Return-on-Tangible-Asset

POLBF (Poolbeg Pharma) Return-on-Tangible-Asset : -36.98% (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Poolbeg Pharma Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Poolbeg Pharma's annualized Net Income for the quarter that ended in Jun. 2024 was $-5.75 Mil. Poolbeg Pharma's average total tangible assets for the quarter that ended in Jun. 2024 was $15.54 Mil. Therefore, Poolbeg Pharma's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2024 was -36.98%.

The historical rank and industry rank for Poolbeg Pharma's Return-on-Tangible-Asset or its related term are showing as below:

POLBF' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -33.35   Med: -24.27   Max: -10.89
Current: -33.35

During the past 3 years, Poolbeg Pharma's highest Return-on-Tangible-Asset was -10.89%. The lowest was -33.35%. And the median was -24.27%.

POLBF's Return-on-Tangible-Asset is ranked better than
55.42% of 1503 companies
in the Biotechnology industry
Industry Median: -39.32 vs POLBF: -33.35

Poolbeg Pharma Return-on-Tangible-Asset Historical Data

The historical data trend for Poolbeg Pharma's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Poolbeg Pharma Return-on-Tangible-Asset Chart

Poolbeg Pharma Annual Data
Trend Dec21 Dec22 Dec23
Return-on-Tangible-Asset
-10.89 -23.10 -26.20

Poolbeg Pharma Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Return-on-Tangible-Asset Get a 7-Day Free Trial -14.86 -32.88 -23.05 -29.92 -36.98

Competitive Comparison of Poolbeg Pharma's Return-on-Tangible-Asset

For the Biotechnology subindustry, Poolbeg Pharma's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Poolbeg Pharma's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Poolbeg Pharma's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Poolbeg Pharma's Return-on-Tangible-Asset falls into.



Poolbeg Pharma Return-on-Tangible-Asset Calculation

Poolbeg Pharma's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-4.976/( (20.896+17.086)/ 2 )
=-4.976/18.991
=-26.20 %

Poolbeg Pharma's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Jun. 2024 )  (Q: Dec. 2023 )(Q: Jun. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Jun. 2024 )  (Q: Dec. 2023 )(Q: Jun. 2024 )
=-5.746/( (17.086+13.993)/ 2 )
=-5.746/15.5395
=-36.98 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is two times the semi-annual (Jun. 2024) net income data.


Poolbeg Pharma  (OTCPK:POLBF) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Poolbeg Pharma Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Poolbeg Pharma's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Poolbeg Pharma Business Description

Traded in Other Exchanges
Address
42 New Road, Queen Mary BioEnterprises Innovation Centre, London, GBR, E1 2AX
Poolbeg Pharma PLC is a clinical-stage infectious disease pharmaceutical company, with a novel capital-light clinical model which enables to develop of multiple products faster and more cost-effectively than the traditional biotech model. The company aspires to become a one-stop shop for pharma-seeking mid-stage products to license or acquire.